KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Income (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Net Income data on record, last reported at $25.7 million in Q4 2025.

  • For Q4 2025, Net Income rose 176.94% year-over-year to $25.7 million; the TTM value through Dec 2025 reached $156.1 million, up 220.57%, while the annual FY2025 figure was $391.0 million, 72.66% up from the prior year.
  • Net Income reached $25.7 million in Q4 2025 per ACAD's latest filing, down from $71.8 million in the prior quarter.
  • Across five years, Net Income topped out at $71.8 million in Q3 2025 and bottomed at -$113.1 million in Q1 2022.
  • Average Net Income over 5 years is -$12.0 million, with a median of -$20.8 million recorded in 2021.
  • The widest YoY moves for Net Income: up 2900.81% in 2024, down 173.0% in 2024.
  • A 5-year view of Net Income shows it stood at -$43.1 million in 2021, then increased by 3.29% to -$41.7 million in 2022, then skyrocketed by 209.89% to $45.8 million in 2023, then crashed by 173.0% to -$33.4 million in 2024, then soared by 176.94% to $25.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were $25.7 million in Q4 2025, $71.8 million in Q3 2025, and $40.2 million in Q2 2025.